Abstracts tagged "Transition"

Abstract Number: 0657 • ACR Convergence 2021
Assessing Patient Transition Outcomes from a Large Pediatric Rheumatology Center to Adult Healthcare
Mary Robichaux¹, Bernard Danna², Monique Maher², David McDonald¹, Kristiana Nasto¹, Alexander Alexander¹, Ariel Coleman³, Danielle Guffey¹ and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Texas Children's Hospital, Houston, TX
Background/Purpose: Transitioning children with chronic diseases from pediatric to adult healthcare can be a challenging task, with high morbidity and mortality. In response, we have…
Abstract Number: 1798 • ACR Convergence 2021
The Transition to Psoriatic Arthritis: What Factors Predict a Shorter Transition from Psoriasis to Psoriatic Arthritis?
Shashank Cheemalavagu¹, Yuxuan Jin² and Elaine Husni², ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Psoriatic arthritis (PsA) occurs in up to 30% of patients with psoriasis (PsO), and usually follows the development of PsO by an average of…
Abstract Number: 170 • 2020 Pediatric Rheumatology Symposium
Clinical Team Perspectives on the Transition from Pediatric to Adult Care for Patients with Childhood-Onset SLE
Nicole Bitencourt¹, Justin Kramer ², Bonnie Bermas ³, Elizabeth Solow ², Tracey Wright ² and Una Makris ², ¹UT Southwestern Medical Center, Dallas, Texas, ²UT Southwestern Medical Center, Dallas, ³UTSouthwestern Medical Center, Dallas
Background/Purpose: The transition from pediatric to adult care for youth with chronic disease is known to be a vulnerable period, with adverse outcomes described for…
Abstract Number: 181 • 2020 Pediatric Rheumatology Symposium
Health Care Professionals and Transition to Adulthood for Youth with Juvenile Idiopathic Arthritis
Sabrina Cavallo¹, ¹University of Montreal, Montreal, Canada
Background/Purpose: The transition to adulthood for young people with juvenile idiopathic arthritis (JIA) can be difficult and lead to undesirable outcomes in terms of socio-professional…
Abstract Number: 182 • 2020 Pediatric Rheumatology Symposium
Needs of Youth with Juvenile Idiopathic Arthritis During the Transition to Adulthood
Sabrina Cavallo¹, ¹University of Montreal, Montreal, Canada
Background/Purpose: The transition to adulthood for young people with juvenile idiopathic arthritis (JIA) may be a difficult period with challenges in socio-professional integration and in…
Abstract Number: 187 • 2020 Pediatric Rheumatology Symposium
Perspectives of Adolescents and Young Adults Around Implementing Rheumatology Healthcare Transition: Preliminary Qualitative Findings
Kristine Carandang¹, Courtney Wells ² and Peter Chiraseveenuprapund ³, ¹University of California, San Diego, San Diego, ²St Paul, ³University of California - San Diego, San Diego
Background/Purpose: Nationwide initiatives call for improved healthcare services that empower adolescents to become independent in their health management and remain engaged in healthcare through young…
Abstract Number: 193 • 2020 Pediatric Rheumatology Symposium
Examining Social Loafing and the Free-Rider Effect in Transition Readiness Among Youth with jSLE
Kiana Johnson¹, Anna Richmond ² and Kathleen O'Neil ³, ¹East Tennessee State University, Johnson City, ²Nashville, ³University of Indiana School of Medicine, Indianapolis, Indiana
Background/Purpose: Especially important in the transition process is the role of the providers and parents and providers shifting from that of a manager of health…
Abstract Number: 039 • 2020 Pediatric Rheumatology Symposium
Assessing Patient Self-Reported Transition Readiness in a Large Pediatric Rheumatology Center
Priyanka Moolchandani ¹, Alexander Alexander ¹, Cristina Saez ¹, JaLeen Rogers ², Ariel Coleman ², Anne Dykes ², Miriah Gillispie-Taylor ³ and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, ²Texas Children's Hospital, Houston, ³Levine Children's Hospital, Charlotte
Background/Purpose: Patients with childhood-onset rheumatologic diseases live well into adulthood and need effective transition from pediatric to adult medical providers. Fortunately, predictors of successful transition…
Abstract Number: 057 • 2020 Pediatric Rheumatology Symposium
Transition from Pediatric to Adult Rheumatology: The Clinician as a Fundamental Ally
Teresa Semalulu ¹, Karen Beattie ¹, Jeanine McColl ¹, Arzoo Alam ², Steffy Thomas ¹, Julie Herrington ³, Jan Willem Gorter ¹, Tania Cellucci ¹, Stephanie Garner ¹, Liane Heale ⁴, Mark Matsos ¹ and Michelle Batthish¹, ¹McMaster University, Hamilton, Canada, ²McMaster University, Mississauga, Canada, ³Hamilton, Canada, ⁴McMaster University, Toronto, Canada
Background/Purpose: The transition from pediatric to adult rheumatology is linked to poor outcomes in the absence of comprehensive transition programs. Several tools are available to…
Abstract Number: 083 • 2020 Pediatric Rheumatology Symposium
Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care
Marla Guzman¹, Anne Eberhard ¹ and Joyce Hui-Yuen ², ¹Cohen Children's Medical Center, Lake Success, ²Cohen Children's Medical Center, New Hyde Park
Background/Purpose: Transition of pediatric lupus (pSLE) patients from pediatric to adult rheumatology care is historically difficult and challenging. We aim to investigate disease activity and…
Abstract Number: 159 • 2020 Pediatric Rheumatology Symposium
Interleukin-18 as a Key Cytokine to Understand Pathology and to Decide Appropriate Therapeutic Strategy in Chronic Arthritic Systemic Juvenile Idiopathic Arthritis
Takako Miyamae¹, Yumi Tani ¹, Manabu Kawamoto ², Takayuki Kishi ³ and Masayoshi Harigai ², ¹Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, TOKYO, Japan, ³Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Long-term outcomes of systemic JIA are highly variable. approximately half of the patients have chronic persistent arthritis requiring extended anti-inflammatory therapy, sometimes into adulthood.…
Abstract Number: 536 • 2019 ACR/ARP Annual Meeting
PERFUSE: A French Prospective/Retrospective Non-interventional Cohort Study of Infliximab-naïve and Transitioned Patients Receiving Infliximab Biosimilar SB2; An Interim Analysis
Bruno Fautrel¹, Yoram Bouhnik ², Guillaume Desjeux ³, Ulrich Freudensprung ⁴, Janet Addison ⁵ and Amira Brigui ⁶, ¹Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ²Beaujon Hospital, Department of Gastroenterology, AP-HP, Paris Diderot University, Clichy, France, ³E-health Services Sanoïa, Digital CRO, Gémenos, France, ⁴Biogen International GmbH, Zug, Switzerland, ⁵Biogen UK, Maidenhead, United Kingdom, ⁶Biogen France SAS, Paris, France
Background/Purpose: SB2 is approved in the EU as an infliximab (IFX) biosimilar, having demonstrated bioequivalence and similar efficacy, safety and immunogenicity as the reference. There…
Abstract Number: 542 • 2019 ACR/ARP Annual Meeting
‘BENEFIT’ Pan-European Observational Study to Evaluate the Real-world Effectiveness of SB4 Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Switch Success Story
Carlo Selmi ¹, Klaus Krüger², Alain Cantagrel ³, Abad Hernández ⁴, Ulrich Freudensprung ⁵, Mourad Farouk Rezk ⁵ and Janet Addison ⁶, ¹Humanitas Research Hospital, University of Milan, Milan, Italy, ²Medical Centre of Rheumatology, Munich, Germany, ³Center of Rheumatology of CHU, Toulouse, France, ⁴FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain, ⁵Biogen International GmbH, Zug, Switzerland, ⁶Biogen UK, Maidenhead, United Kingdom
Background/Purpose: SB4, a biosimilar to the reference ETN, received EU marketing authorisation in January 2016, based on the totality of evidence from pre-clinical and clinical…
Abstract Number: 1127 • 2019 ACR/ARP Annual Meeting
Interventions to Improve Time to Appointment and Outcome Variables in the Pediatric to Adult Transition of Care in Rheumatology
Nicole Bitencourt¹, Una Makris ², Bonnie Bermas ³, Tracey Wright ⁴ and Elizabeth Solow ⁵, ¹UT Southwestern Medical Center, Dallas, ²UT Southwestern Medical Center and Dallas VA Medical Center, Dallas, ³UT Southwestern, Dallas, ⁴University of Texas Southwestern, Texas Scottish Rite Hospital for Children, Children's Health, Dallas, TX, ⁵UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The transition from pediatric to adult care is a vulnerable period, in which poor health outcomes are reported amongst youth transferring to adult care.…
Abstract Number: 1189 • 2019 ACR/ARP Annual Meeting
Baylor Rheumatology Initiative: Developing and Guiding Engagement (BRIDGE) Transition Pathway Creation and Implementation
Priyanka Moolchandani¹, Cristina Saez ¹, Marietta DeGuzman ¹, Eyal Muscal ¹, Andrea Ramirez ¹, Anna Carmela Sagcal-Gironella ¹, Saimun Singla ¹, Amanda Brown ¹, Monica Marcus ¹, Martha Curry ¹, Maria Pereira ¹, M. Brad Nelson ¹, Pooja Patel ¹, W. Blaine Lapin ¹, Jennifer Rammel ¹, LeeGee Huang ², Blanca Sanchez-Fournier ², JaLeen Rogers ², Ariel Washington ², Anne Dykes ², Miriah Gillispie-Taylor ¹ and Tiphanie Vogel ¹, ¹Baylor College of Medicine, Houston, TX, ²Texas Children's Hospital, Houston, TX
Background/Purpose: Patients with pediatric rheumatologic diseases live well into adulthood, necessitating transition from pediatric to adult medical providers. GotTransition.org details 6 core elements clinicians can…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].